GSK Says Lung-Cancer Drug Shows Benefits in Global Trial

GSK's experimental lung cancer drug, Ris-Rez, showed a 61% response rate in a small global trial, with higher doses causing more severe side effects. The drug is being tested in patients with extensive-stage small cell lung cancer who had relapsed after previous treatments. GSK plans to present the findings at the European Society for Medical Oncology Congress 2026.

GSK (LSE/NYSE:GSK) reported positive phase 1b trial data for risvutatug rezetecan, a lung cancer drug candidate, showing a 61% response rate at 8 mg/kg dose. The trial involved 50 patients with relapsed extensive-stage small cell lung cancer. GSK plans to proceed with a global phase III study using the 8 mg/kg dose. The company acquired rights to the drug from Hansoh Pharma, excluding certain regions.

GSK PLC reported that its experimental lung cancer drug, risvutatug rezetecan, showed a 61% response rate in an early-stage global trial at the higher dose tested. The company is using the higher dose in its ongoing phase III study and has seen manageable safety profiles. GSK acquired rights to the drug outside certain regions and is evaluating it for multiple cancer indications.

GSK reported positive early data for its investigational drug Ris-Rez in extensive-stage small cell lung cancer, showing a 61% overall response rate in a phase Ib trial. The results support accelerated development, including an ongoing global phase III trial. GSK aims to advance targeted medicines for cancers with high unmet needs.

GSK reported positive Phase Ib results for risvutatug rezetecan, an antibody-drug conjugate for relapsed extensive-stage small cell lung cancer, with a 61% ORR at 8 mg/kg dose. The company has a 3.6% dividend yield, a 39% payout ratio, and a GF Score of 78/100. GSK is fairly valued with a GF Value of $45.26 vs. market price of $49.51. Guru activity is mixed, with 15 holding, 10 trimming, and 6 adding positions.

GSK presented global data for its investigational drug Ris-Rez in extensive-stage small cell lung cancer. The phase Ib trial showed a 61% objective response rate at the 8 mg/kg dose, with a manageable safety profile. The data will be presented at the ESMO Congress 2026 and support the ongoing phase III EMBOLD SCLC-301 study.